CYSLTR1 - cysteinyl leukotriene receptor 1 Gene
Also Known as CYSLT1; CYSLTR; CYSLT1R; HMTMF81
Species: Homo sapiens
About CYSLTR1
This gene has 3 transcripts (splice variants), 177 orthologues and 16 paralogues. Broad expression in urinary bladder (RPKM 6.1), spleen (RPKM 5.2) and 20 other tissues.
Summary
This gene encodes a member of the G-protein coupled receptor 1 family. The encoded protein is a receptor for cysteinyl leukotrienes, and is involved in mediating bronchoconstriction via activation of a phosphatidylinositol-calcium second messenger system. Activation of the encoded receptor results in contraction and proliferation of bronchial smooth muscle cells, eosinophil migration, and damage to the mucus layer in the lung. Upregulation of this gene is associated with asthma and dysregulation may also be implicated in Cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]
CYSLTR1 Products (4)
| mRNA | Protein | Name |
|---|---|---|
| NM_001282186.2 | NP_001269115.1 | cysteinyl leukotriene receptor 1 |
| NM_001282188.2 | NP_001269117.1 | cysteinyl leukotriene receptor 1 |
| NM_001282187.2 | NP_001269116.1 | cysteinyl leukotriene receptor 1 |
| NM_006639.4 | NP_006630.1 | cysteinyl leukotriene receptor 1 |
CYSLTR1 Protein Structure
7tm_1: 7 transmembrane receptor (rhodopsin family) (40 - 295)
- 0
- 100
- 200
- 300
- 337 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
cysteinyl leukotriene receptor 1 |
|
|
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Aspirin-Induced Respiratory Disease |
|
|
| Vulvar Keratoacanthoma-Like Carcinoma |
|
|
| Pulmonary Eosinophilia |
|
|
| Acute Asthma |
|
|
| Vernal Conjunctivitis |
|
|
| Adenoid Hypertrophy |
|
|
| Respiratory Allergy |
|
|
| Bronchial Disease |
|
|
| Nasal Cavity Disease |
|
|
| Respiratory Failure |
|
|
| Intrinsic Asthma |
|
|
| Monocytic Leukemia |
|
|
| Asthma |
|
|
| Angioedema |
|
|
| Chronic Asthma |
|
|
| Persistent Mild Asthma |
|
|
| Urticaria |
|
|
| Intermittent Asthma |
|
|
| Dermatitis, Atopic |
|
|
| Exercise-Induced Bronchoconstriction |
|
|
| Rhinitis |
|
|
| Asthma, Nasal Polyps, And Aspirin Intolerance |
|
|
| Nose Disease |
|
|
Related Agents
- Approval
- Pre-clinical Phase
Approval
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-13315A | Montelukast | Antagonist | 99.94% | Yes |
| HY-13315 | Montelukast sodium | Antagonist | 99.84% | Yes |
| HY-13315B | Montelukast dicyclohexylamine | Antagonist | / | Unkown |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-13315S1 | Montelukast-d6 sodium | Antagonist | ≥96.0% | Unkown |
| HY-13315S | Montelukast-d6 | Antagonist | / | Unkown |
| HY-19395 | MEN-91507 | Antagonist | / | Unkown |
| HY-RS03494 | CYSLTR1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03495 | Cysltr1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03496 | Cysltr1 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service